LAVAL, Quebec, May 3, 2017 /CNW/ -- Valeant Pharmaceuticals
International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the
"Company") announced today the election of the ten directors
nominated at its 2017 annual meeting of shareholders held on
May 2, 2017. The detailed results of
the vote for the election of directors are set out below:
|
Name
|
|
For
|
|
Withheld
|
|
Broker
Non-Votes
|
|
|
|
|
|
|
|
|
|
|
Richard U.
DeSchutter
|
|
123,623,109
|
|
5,319,736
|
|
98,872,954
|
|
|
Dr. Frederic N.
Eshelman
|
|
126,125,069
|
|
2,817,776
|
|
98,872,954
|
|
|
D. Robert
Hale
|
|
123,127,211
|
|
5,815,634
|
|
98,872,954
|
|
|
Dr. Argeris (Jerry)
N. Karabelas
|
|
123,529,948
|
|
5,412,897
|
|
98,872,954
|
|
|
Sarah B.
Kavanagh
|
|
126,292,442
|
|
2,650,403
|
|
98,872,954
|
|
|
Joseph C.
Papa
|
|
123,983,101
|
|
4,959,744
|
|
98,872,954
|
|
|
Robert N.
Power
|
|
125,649,938
|
|
3,292,907
|
|
98,872,954
|
|
|
Russel C.
Robertson
|
|
126,590,227
|
|
2,352,618
|
|
98,872,954
|
|
|
Thomas W. Ross,
Sr.
|
|
126,166,299
|
|
2,776,546
|
|
98,872,954
|
|
|
Amy B. Wechsler,
M.D.
|
|
123,473,243
|
|
5,469,602
|
|
98,872,954
|
|
At the annual meeting, shareholders also approved the
non-binding advisory vote on named executive officer compensation
and an annual frequency of advisory votes on the compensation of
our named executive as disclosed in the proxy statement and
appointed PricewaterhouseCoopers LLP as the Company's independent
registered public accounting firm until the close of the Company's
2018 annual meeting of shareholders.
The final vote tabulation on all matters voted on at the meeting
will be reported to the U.S. Securities and Exchange Commission on
a current report on Form 8-K and such report will be made available
on the Company's web site at www.valeant.com.
About Valeant
Valeant Pharmaceuticals International,
Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical
company that develops, manufactures and markets a broad range of
pharmaceutical products primarily in the areas of dermatology,
gastrointestinal disorders, eye health, neurology and branded
generics. More information about Valeant can be found at
www.valeant.com.
Contact Information:
Elif McDonald
elif.mcdonald@valeant.com
514-856-3855
877-281-6642 (toll free)
Media:
Renée Soto
or
Chris Kittredge/Jared Levy
Sard Verbinnen & Co.
212-687-8080
SOURCE Valeant Pharmaceuticals International, Inc.